Results from Turkish clinical cohorts | ||||||
---|---|---|---|---|---|---|
Cohort | Clinical definition | Number (percentage) responding to antigen | ||||
ESAT-6 | CFP8A | Acr: MPT83 | ORF3 | Any antigen | ||
TB patients (n = 99) | Pulmonary (n = 91) | 17 (18.6%) | 9 (9.8%) | 40 (43.9%) | 5 (5.5%) | 45 (45.5%) |
Extra-pulmonary (n = 8) | 0 (0%) | 0 (0%) | 2 (25%) | 0 (0%) | 2 (25%) | |
TB contacts (n = 48) | PPD+, known exposure (n = 48) | 4 (8.5%) | 2 (4.2%) | 16 (33.3%) | 2 (4.2%) | 18 (37.5%) |
Community controls (n = 153) | Symptomatic, non-TB (n = 8) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Healthy, no identified exposure (n = 145) | 6 (4.2%) | 2 (1.4%) | 15 (9.1%) | 1 (0.7%) | 18 (11.8%) | |
Results from Ethiopian clinical cohorts | ||||||
Cohort | Clinical definition | Number (percentage) responding to antigen | ||||
ESAT-6 | CFP8A | Acr: MPT83 | ORF3 | Any antigen | ||
TB patients (n = 79) | Pulmonary (n = 48) | 9 (18.8%) | 5 (10.4%) | 24 (50.0%) | 0 (0%) | 26 (54.2%) |
Extra-pulmonary (n = 31) | 4 (12.9%) | 2 (0.65%) | 12 (38.7%) | 0 (0%) | 12 (38.7%) | |
TB contacts (n = 73) | Known exposure (n = 73) | 4 (8.48%) | 2 (4.16%) | 19 (26.0%) | 0 (0%) | 21 (28.8%) |
Community controls (n = 60) | Healthy, no identified exposure (n = 60) | 6 (4.19%) | 2 (1.39%) | 12 (20.0%) | 0 (0%) | 16 (26.7%) |